Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 14/20 | 0.50 |
| ▸ | S1PR3 | Q99500 | 4/20 | 0.50 |
| ▸ | HDAC4 | P56524 | 4/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 4/20 | 0.46 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3091280 | 0.91 | S1PR1 (0.53) | S1PR1S1PR3HDAC4HDAC6 | |
| SCHEMBL4617985 | 0.77 | S1PR1 (0.45) | S1PR1S1PR3HDAC4HDAC6MAPT | |
| SCHEMBL4618867 | 0.76 | S1PR1 (0.45) | S1PR1S1PR3CA1CA2CA9 | |
| SCHEMBL4923643 | 0.76 | PTGS2 (0.45) | S1PR1S1PR3HDAC4HDAC6MAPT | |
| SCHEMBL3275517 | 0.76 | S1PR1 (0.42) | S1PR1S1PR5MAPT | |
| SCHEMBL4618138 | 0.74 | S1PR1 (0.70) | S1PR1S1PR3CA12CA1CA2 | |
| SCHEMBL3273937 | 0.73 | S1PR1 (0.49) | S1PR1S1PR3S1PR5 | |
| SCHEMBL3082641 | 0.72 | S1PR1 (0.73) | S1PR1S1PR3S1PR5 | |
| SCHEMBL3103302 | 0.72 | S1PR1 (0.64) | S1PR1S1PR3MAPT | |
| SCHEMBL14089928 | 0.71 | S1PR1 (0.61) | S1PR1S1PR3S1PR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2233473-A1 | 3,5-di(aryl or heteroaryl)isoxazoles and 1,2,4-oxadiazoles as S1P1 receptor agonists, immunosuppresssive and anti-inflammatory agents | Novartis AG (CH) | 2010-09-29 | — | — | EP | disclosed |
| US-7799812-B2 | Reverse isoxazoles | NOVARTIS AG (CH) | 2010-09-21 | — | — | US | disclosed |
| EP-1981858-B1 | 3,5-DI(ARYL OR HETEROARYL)ISOXAZOLES AND 1,2,4-OXADIAZOLES AS S1P1 RECEPTOR AGONISTS, IMMUNOSUPPRESSSIVE AND ANTI-INFLAMMATORY AGENTS | NOVARTIS AG (CH) | 2010-06-16 | — | — | EP | disclosed |
| US-20090137636-A1 | Reverse Isoxazoles | NOVARTIS AG | 2009-05-28 | — | — | US | disclosed |
| EP-1981858-A2 | 3,5-DI(ARYL OR HETEROARYL)ISOXAZOLES AND 1,2,4-OXADIAZOLES AS S1P1 RECEPTOR AGONISTS, IMMUNOSUPPRESSSIVE AND ANTI-INFLAMMATORY AGENTS | Novartis AG (CH) | 2008-10-22 | — | — | EP | disclosed |
| WO-2007085451-A2 | 3,5-DI (ARYL OR HETEROARYL) ISOXAZOLES AND 1, 2, 4-OXADIAZOLES AS S1P1 RECEPTOR AGONISTS, IMMUNOSUPPRESSSIVE AND ANTI -INFLAMMATORY AGENTS | NOVARTIS AG (CH) | 2007-08-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137636-A1 | Reverse Isoxazoles | CYP3A7, CYP3A4, TBXA2R | S1PR1 3804/4885S1PR3 2578/4885HDAC4 708/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.